The U.S. pharmaceutical industry is enormous. A recent analysis placed its 2025 market value at roughly $520 billion, making it the world’s largest national drug market. Government protection of the industry is achieved in part through enforcement of Schedule I — Title VII of the Reauthorization Act of 1998 which discourages legalizing natural medicines that might compete with patented U.S. pharmaceutical products.
A company that owns a drug patent (intellectual property) is awarded a marketing monopoly for 20 years. Natural substances that have existed for millions of years are sidelined because naturally occurring chemicals are not allowed to be patented in raw form. A marketing strategy overcoming the patentability roadblock involves synthesizing drug analogs of the original substance.
A classic example is Marinol, a drug designed as a pharmaceutical substitute for plant-derived THC and other cannabinoids. Marinol (dronabinol) achieved regulatory legitimacy and steady niche sales, but never became a dominant market force due to competition from natural cannabis, side‑effect concerns, and very limited patient enthusiasm for dronabinol.
The ONDCP is a major policy‑shaping agency. It walls off Big Pharma’s natural competitors, especially if the drugs function as antidepressants, anti-anxiety medications, or alternative non-addictive painkillers. ONDCP’s legal mandate is strictly prohibitionist. A Schedule I drug ranking requires that there be “no accepted medical use,” which becomes self‑reinforcing when research that might prove otherwise is discouraged. The ONDCP cannot pivot toward medical research and medicinal recognition of an illicit drug without legislative change or an executive mandate. Title VII of the applicable federal code restricts the ONDCP from funding research or supporting the legalization of Schedule I drugs in any form. However, the research prohibition does not extend to research performed by the NIH or FDA.
The alternative FDA approval pathway mentioned in Title VII that allows a naturally occurring drug to be distributed is expensive to navigate. Extensive clinical trials are required investigating safety and effectiveness, all of which require funding. This process is comparable to a pharmaceutical company spending $500 million to develop a new drug. The parent company seeks reimbursement for its research investment by charging enormous prices for the final product. This drives up the cost of health care. Lower-cost competition can sometimes be stifled.
Actively suppressing economic competition is illegal in the United States when the conduct meets the definitions of anticompetitive activities. The U.S. has three major statutes that provide definitions: the Sherman Act, the Clayton Act, and the Federal Trade Commission Act. Federal and state governments are allowed under Title VII to deprive American citizens of safe, effective, low-cost medications.
Overcoming the antitrust laws involves dealmaking with legislators seeking campaign funding or other types of political clout. What emerges is a racket. The door is opened for dark money contributions used to hire propagandists whose job is to make sure some of the best and most economical drugs never reach consumers. Their propaganda gives mixed results. Anti-drug propaganda can easily be vilified simply as a result of legal authorities running amok who embarrass themselves by arresting or killing the wrong people. Drug war examples are abundant. Recently the enforcers added insult to injury by arresting an internationally recognized former Olympic skier, Bode Miller, for possessing magic mushrooms.
It appears nearly impossible to estimate the total financial, emotional, and social damage the drug war has caused in just the last fifty years. It is anyone’s guess how many illnesses could have been treated had cannabis always been legal, or how many cases of PTSD or suicides might have been prevented had psychedelics been easily accessible. Drug wars in one form or another have existed for centuries. The wars can originate from conflicting religious ideologies or from trade monopolies exemplified by the marketing of opium by the British East India Company. Tribalism, xenophobia, and individual attachments to social identities also play crucial roles.
Theocrats and political dictators who rely on public fear and ignorance to perpetuate their professional survival are terrified of any drug that can open a person’s mind and imagination to what can be better or more useful. Despots are likely to oppose whatever is meant by “recreational” or “mind expanding” drug use because they view a citizen’s happiness and well-being as a kind of unorthodoxy leading to behavior that could remove them from power. A dictator’s political hold on people requires that they be kept miserable and insecure and prone to seeking out scapegoats that don’t include their present leaders. People want tyrants to deliver on their initial promises of paradise and then go away. After all, who needs a clueless mob of hysterical government authoritarians messing with people’s lives and happiness when everything else is going well?
There are many political remedies that can add up to stopping a drug war. For instance, deposing tyrants is easier in a democracy. In the USA voters still enjoy the privileges of challenging the outrageous charges of chemical treason being leveled against them. They can openly protest online, in the newsrooms, and in the courtrooms. They can educate the public with real facts about recreational drugs. They can undo lies about drugs spread by the DEA and ONDCP. They can promote less expensive health care when it is available. They can demand enforcement of the anti-trust laws with respect to pharmaceutical corporations and natural drugs. To these ends they can ensure their own excellent health, their safety, and that of others by refusing to elect leaders who stand to gain from drug wars which serve only to increase human suffering and ruin.
[…] the Drug Czar is Required by Law to Lie […]